Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Prostate cancer often exhibits constitutive activation of the PI3K/Akt signaling pathway.
• Mutations in the PTEN gene are a common driver of this aberrant pathway activation.
• Targeting this pathway presents a promising therapeutic avenue for prostate cancer treatment.

Purpose of the Study:

• To review current therapeutic interventions for prostate cancer that address PI3K/Akt pathway activation.
• To specifically examine strategies compensating for PTEN gene mutations.
• To evaluate the applicability of various targeted inhibitors in this context.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of therapeutic agents targeting key nodes in the PI3K/Akt pathway.
• Focus on inhibitors of Epidermal Growth Factor Receptor (EGF-R) tyrosine kinase, Cyclooxygenase-2 (COX-2), Phosphoinositide-dependent kinase-1 (PDK-1), Mammalian Target of Rapamycin (mTOR), and farnesyltransferase.

Main Results:

• Several therapeutic interventions show potential for compensating PI3K/Akt pathway activation.
• Inhibitors targeting EGF-R tyrosine kinase, COX-2, PDK-1, mTOR, and farnesyltransferase are under investigation.
• The efficacy of these agents is particularly relevant in prostate cancers with PTEN mutations.

Conclusions:

• Targeted inhibition of the PI3K/Akt pathway is a key strategy in advanced prostate cancer therapy.
• Specific inhibitors, including those for EGF-R, COX-2, PDK-1, mTOR, and farnesyltransferase, warrant further clinical evaluation.
• Personalized therapeutic approaches based on genetic mutations like PTEN are crucial for effective prostate cancer treatment.